To meet the challenge of the increase of chronic diseases, the increase of elderly patient population and the sustainability of the healthcare system, it appears that ambulatory/home cares development and oral drugs administration at home for the treatment and the management of serious diseases are the major orientation of healthcare system worldwide.
In this situation, patient and healthcare professionnals (hospital sector and ambulatory sector) need an efficient information system for an optimal organisation of cares and for an appropriate patients follow-up, checking adherence to the treatment and early alerting of adverse events or complications. In addition, oral drugs for treating serious diseases are more and more available for prescriptions by healthcare professionnals. These oral drugs are complex in terms of scheme of administration and need a close monitoring for adverse event prevention or management.
To cover this need and meet such evolution, the development is on-going for a patient-centric digital solution integrating a connected device. This solution monitors and delivers at home oral drugs in a secure way. It is associated with a remote-care software which shares clinical data, biological data, treatment data and patient-reported outcomes between all healthcare professionnals and the patient.
The application of the offer could be tailored for any diseases treated with oral drugs in at risk patients population who need scrutiny.
At the moment, experiments are led in oncology in 2 centers in France and in nephrology in renal failure in one care-network in France. The patient-centered approaches applied to the development of the remote-care software are positive for the patients and are communicated in a poster during a conference in psycho-oncology in November 2019.
The offer is adaptable: it could be the connected device alone associated with a remote-care software developed by a partner or our remote-care software alone for the digital coordination of cares and patients reported outcomes (treatment adherence included) or both of them.
The partnership could be with:
- healthcare institutions which have the project to implement digital organisation of cares,
- others SMEs which want to integrate remote-care sofware technologie or connected device with their apps to monitor adherence to drug and surveillance of patients,
- pharma companies in the frame of their randomized clinical trials or of their study in real life conditions.
The company is interested in technical cooperation agreement, research cooperation agreement or commercial agreement with technical assistance.